Upsetting the apple CAR‐T (chimeric antigen receptor T‐cell therapy) ‐ sustainability mandates USA innovation. (1st May 2020)

• Record Type: Journal Article
• Authors: Pantin, Jeremy; Battiwalla, Minoo
• Is Part Of: British journal of haematology. Volume 190:Number 6(2020)
• Page Start: 851
• Page End: 853
• Publication Date: 2020-05-01
• Subjects: CAR‐T -- immune effector cell therapy -- Health economics and outcomes research -- health economics -- sustainability; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.16685
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Seldom has a medical advance in cancer therapy been as pivotal as the advent of chimeric antigen receptor (CAR)‐T‐cell immunotherapy. While the first applications targeted the CD19 antigen on lymphoid malignancies, the incredible specificity of these 'living drugs', curative potential and generalisability to other targets have richly justified their declaration as 2019's breakthrough of the year by Science magazine. Two CAR‐T products, Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel) were Food and Drug Administration (FDA)‐approved in the USA in late 2017, with the FDA commissioner Scott Gottlieb heralding 'a new frontier in medical innovation with the ability to reprogram a patient's own cells to attack a deadly cancer'. Building upon early enthusiasm, nearly 1000 cell‐ and gene‐therapy investigational new drug applications are pending with the FDA, which expects to review and approve between 10 and 20 such treatments annually by 2025. Despite the enormous promise and urgent unmet need fulfilled by CAR‐T cells, the real‐world adoption of the two FDA‐approved treatments has been slow.